
Opinion|Videos|July 16, 2024
Navigating Biosimilar Uptake in New Patients
The panel discuss if including biosimilars on formulary at parity is enough to support their adoption.
Advertisement
Video content above is prompted by the following:
- How do you direct new-start patients to a biosimilar? What about switching?
- Payers require generic medications over brand name in most instances. Why isn’t this the case for biosimilars?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
4
Pricing and Insurance Networks in Outpatient Surgery Markets
5